News

(RTTNews) - Cartesian Therapeutics, Inc. (RNAC) announced the FDA has granted Regenerative Medicine Advanced Therapy designation for Descartes-08 for the treatment of myasthenia gravis. Descartes-08 was previously granted Orphan Drug Designation for the treatment of MG. The company said it remains on track to report topline data from Phase 2b randomized, double-blind, placebo-controlled trial of Descartes-08 in patients with MG in mid-2024.

Carsten Brunn, CEO of Cartesian, said: "We look forward to working closely with the FDA to efficiently advance the development of Descartes-08 for this underserved population."

Shares of Cartesian are up 4% in pre-market trade on Wednesday.

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.